10th Annual NGS & Clinical Diagnostics Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 10thAnnual NGS & Clinical Diagnostics Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences

CIDP (Centre International de Développement Pharmaceutique)

Mauritius, the tropical island situated in the Indian Ocean and known worldwide for its beautiful beaches, is also internationally recognised for its rule of law, and political and social stability. Over the past few years, the economy has been successfully transitioned from a monocrop to a diversified innovation-driven and knowledge-based economy, resting on agribusiness, export-oriented manufacturing, tourism, financial services, property development and real estate, ICT-BPO, the seafood industry, a free port, logistics and a nascent ocean economy. Emerging sectors such as healthcare and life sciences are presenting some niche areas for the taking, and the enabling environment is being put in place to make it happen - especially in the light of sustained growth within pharmaceutical, medical device, and clinical research. Important international players are already in operation locally as the country has established the appropriate legal and regulatory frameworks based on international norms, for the development of a strong biomedical research sector.
More info >>

PCI Pharma Services Announces Serialization Installation at Tredegar Manufacturing Center of Excellence

PCI Pharma Services (PCI) is pleased to announce the installation and validation of its latest comprehensive Serialization system, located at its manufacturing Center of Excellence in Tredegar, UK.  The investment demonstrates PCI’s continued investment in and expansion of market-leading Serialization capabilities. This latest installation increases PCI’s Serialization capability to support clients in advance of implementation dates for the European Falsified Medicines Directive (EU FMD), as well as supply for the US and emerging markets, including countries such as China, Turkey, Brazil, Saudi Arabia and others.  PCI’s system is compliant to all EU member country requirements for Serialization and specialized labeling, including application and integration of advanced Anticounterfeiting technologies.
More info >>